Syndax Pharmaceuticals, Inc. Financials

Market Capitalization $774.4 Million as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE
Forward PE	-2.54
Price to Sales TTM	$17.71
Price to Book MRQ	$3.60
Enterprise to Revenue	14.53
Enterprise to EBITDA	-1.85

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	96.51%
Operating Margin	-416.68%
Return on Assets TTM	-36.29%
Return on Equity TTM	-93.70%

Income Statement

Revenue TTM	$43,722,000
Revenue per Share TTM	$0.51
Quarterly Revenue Growth	160.96%
Gross Profit TTM	$-199,636,000
EBITDA	$-343,660,992
Net Income to Common TTM	$-331,204,000
Diluted EPS TTM	$-3.85
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$516,312,992
Total Cash per Share MRQ	$6.00
Total Debt MRQ	$
Total Debt to Equity MRQ	160.71
Current Ratio MRQ	5.80
Book Value per Share MRQ	$2.50

Cash Flow

Operating Cash Flow TTM	$-286,516,992
Levered Free Cash Flow TTM	$-169,649,632

SNDX Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	85,694,443
Float Shares	76,947,071
Avg 10 Volume	2,134,640
Avg 30 Volume	None
Shares Short	22,003,021
Short Ratio	9.96
Short % of Shares	28.88%
% Held by Insiders	1.30%
% Held by Institutions	120.79%

Stock Price Summary

Beta	0.75
Fifty Two Week Low	$8.58
Fifty Two Week High	$25.07
Fifty Two Week Change	-134.78%
Day 50 MA	$10.71
Day 200 MA	$14.26

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date